Heterogeneous in vivo expression of clumping factor A and capsular polysaccharide by Staphylococcus aureus: Implications for vaccine design

Vaccine

Volumn 27, Issue 25-26, 2009, Pages 3276-3280

  Nanra, Jasdeep S ^a   Timofeyeva, Yekaterina ^a   Buitrago, Sandra M ^a   Sellman, Bret R ^a   Dilts, Deborah A ^a   Fink, Pamela ^a   Nunez, Lorna ^a   Hagen, Michael ^a   Matsuka, Yury V ^a   Mininni, Terri ^a   Zhu, Duzhang ^a   Pavliak, Viliam ^a   Green, Bruce A ^a   Jansen, Kathrin U ^a   Anderson, Annaliesa S ^a  

^a WYETH RESEARCH   (United States)

Author keywords

Antigen; S. aureus; Vaccine

Indexed keywords

ANTIGEN; CLUMPING FACTOR A; POLYSACCHARIDE; STAPHYLOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BACTEREMIA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VIVO CULTURE; MICROENVIRONMENT; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; WOUND INFECTION;

ANIMALS; ANTIGENS, BACTERIAL; BACTEREMIA; BACTERIAL CAPSULES; COAGULASE; DRUG DESIGN; FEMALE; HL-60 CELLS; HUMANS; MICE; MICE, INBRED C57BL; PHAGOCYTOSIS; STAPHYLOCOCCAL VACCINES; STAPHYLOCOCCUS AUREUS;

EID: 67349273615     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.01.062     Document Type: Article

References (27)

1. Dryla A., Prustomersky S., Gelbmann D., Hanner M., Bettinger E., Kocsis B., et al. Comparison of antibody repertoires against Staphylococcus aureus in healthy individuals and in acutely infected patients. Clin Diagn Lab Immunol 12 3 (2005) 387-398
2. Verbrugh H.A., Peterson P.K., Nguyen B.Y., Sisson S.P., and Kim Y. Opsonization of encapsulated Staphylococcus aureus: the role of specific antibody and complement. J Immunol 129 4 (1982) 1681-1687
3. Stephan F., Yang K., Tankovic J., Soussy C.J., Dhonneur G., Duvaldestin P., et al. Impairment of polymorphonuclear neutrophil functions precedes nosocomial infections in critically ill patients. Crit Care Med 30 2 (2002) 315-322
4. Cunnion K.M., Zhang H.M., and Frank M.M. Availability of complement bound to Staphylococcus aureus to interact with membrane complement receptors influences efficiency of phagocytosis. Infect Immun 71 2 (2003) 656-662
5. Cunnion K.M., Benjamin Jr. D.K., Hester C.G., and Frank M.M. Role of complement receptors 1 and 2 (CD35 and CD21), C3, C4, and C5 in survival by mice of Staphylococcus aureus bacteremia. J Lab Clin Med 143 6 (2004) 358-365
6. Middleton J.R. Staphylococcus aureus antigens and challenges in vaccine development. Expert Rev Vac 7 6 (2008) 805-815
7. Thakker M., Park J.S., Carey V., and Lee J.C. Staphylococcus aureus serotype 5 capsular polysaccharide is antiphagocytic and enhances bacterial virulence in a murine bacteremia model. Infect Immun 66 11 (1998) 5183-5189
8. Roghmann M., Taylor K.L., Gupte A., Zhan M., Johnson J.A., Cross A., et al. Epidemiology of capsular and surface polysaccharide in Staphylococcus aureus infections complicated by bacteraemia. J Hosp Infect 59 1 (2005) 27-32
9. Fattom A., Schneerson R., Watson D.C., Karakawa W.W., Fitzgerald D., Pastan I., et al. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect Immun 61 3 (1993) 1023-1032
10. Lee J.C., Park J.S., Shepherd S.E., Carey V., and Fattom A. Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats. Infect Immun 65 10 (1997) 4146-4151
11. Fattom A.I., Sarwar J., Ortiz A., and Naso R.A. Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect Immun 64 5 (1996) 1659-1665
12. Han H.R., and Pak II S. Guidry A. Prevalence of capsular polysaccharide (CP) types of Staphylococcus aureus isolated from bovine mastitic milk and protection of S. aureus infection in mice with CP vaccine. J Vet Med Sci 62 12 (2000) 1331-1333
13. Foster T.J., and Hook M. Surface protein adhesins of Staphylococcus aureus. Trends Microbiol 6 12 (1998) 484-488
14. Josefsson E., Higgins J., Foster T.J., and Tarkowski A. Fibrinogen binding sites P336 and Y338 of clumping factor A are crucial for Staphylococcus aureus virulence. PLoS ONE 3 5 (2008) e2206
15. Arrecubieta C., Matsunaga I., Asai T., Naka Y., Deng M.C., and Lowy F.D. Vaccination with clumping factor A and fibronectin binding protein A to prevent Staphylococcus aureus infection of an aortic patch in mice. J Infect Dis 198 4 (2008) 571-575
16. Kuklin N.A., Clark D.J., Secore S., Cook J., Cope L.D., McNeely T., et al. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect Immun 74 4 (2006) 2215-2223
17. Shinefield H.R. Use of a conjugate polysaccharide vaccine in the prevention of invasive staphylococcal disease: is an additional vaccine needed or possible?. Vaccine 24 Suppl. 2:S2 (2006) 65-69
18. Kiser K.B., Cantey-Kiser J.M., and Lee J.C. Development and characterization of a Staphylococcus aureus nasal colonization model in mice. Infect Immun 67 10 (1999) 5001-5006
19. Arbeit R.D., and Dunn R.M. Expression of capsular polysaccharide during experimental focal infection with Staphylococcus aureus. J Infect Dis 156 6 (1987) 947-952
20. Lee J.C., Takeda S., Livolsi P.J., and Paoletti L.C. Effects of in vitro and in vivo growth conditions on expression of type 8 capsular polysaccharide by Staphylococcus aureus. Infect Immun 61 5 (1993) 1853-1858
21. Hall A.E., Domanski P.J., Patel P.R., Vernachio J.H., Syribeys P.J., Gorovits E.L., et al. Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A. Infect Immun 71 12 (2003) 6864-6870
22. Yokoyama WM, Christensen M, Santos GD, Miller D. Production of monoclonal antibodies. Current protocols in immunology; 2006 [Chapter 2:Unit 2.5].
23. Romero-Steiner S., Libutti D., Pais L.B., Dykes J., Anderson P., Whitin J.C., et al. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 4 4 (1997) 415-422
24. Montgomery C.P., Boyle-Vavra S., Adem P.V., Lee J.C., Husain A.N., Clasen J., et al. Comparison of virulence in community-associated methicillin-resistant Staphylococcus aureus pulsotypes USA300 and USA400 in a rat model of pneumonia. J Infect Dis 198 4 (2008) 561-570
25. Sellman B.R., Timofeyeva Y., Nanra J., Scott A., Fulginiti J.P., Matsuka Y.V., et al. Expression of Staphylococcus epidermidis SdrG increases following exposure to an in vivo environment. Infect Immun 76 7 (2008) 2950-2957
26. Cook J., Hepler R., Pancari G., Kuklin N., Fan H., Wang X.M., et al. Staphylococcus aureus capsule type 8 antibodies provide inconsistent efficacy in murine models of staphylococcal infection. Hum Vaccin 5 3 (2009)
27. Tuchscherr L.P., Buzzola F.R., Alvarez L.P., Lee J.C., and Sordelli D.O. Antibodies to capsular polysaccharide and clumping factor A prevent mastitis and the emergence of unencapsulated and small-colony variants of Staphylococcus aureus in mice. Infect Immun 76 12 (2008) 5738-5744